But challenges with its business model and continued data privacy concerns for consumers have brought the company once valued at $6 billion to a valuation of nearly $0, with Nasdaq threatening to delist it.
WSJ explains what went wrong with Wojcicki’s biotech business.
- 0:00 Home DNA testing
- 0:49 The rise of 23andMe
- 2:18 The turning point
- 4:03 23andMe’s fall
- 5:23 What’s next?
What Went Wrong explores the challenging conditions and decisions that led to a company's downturn.